-
Overview
-
Assays
-
Case Study
-
Regulatory Guidance
-
Experience
-
Instruments and Software
-
FAQs
-
Related Resources
-
Related Services
Overview
The in vivo MetID platform at WuXi AppTec DMPK offers three types of metabolic studies for different experimental purposes: circulation and excreta metabolism study in animals, and clinical metabolism study. In addition, the established in vivo MetID platform has performed metabolite profiling and identification of lead compounds and drug candidates with a variety of structures, including conventional small molecules, high-polar and non-polar small molecules, natural products, nucleotides, Proteolysis-Targeting Chimeras (PROTACs*), polysaccharides, peptides, ADCs, PDCs, oligonucleotides, etc. Sample matrices include whole blood, plasma, urine, feces, bile, tissues, etc.
Learn More
Assays
Case Study
-
-
Metabolite profiles in plasma, urine, and feces of human
Figure1
Result: Figure 1 are metabolite profiling and ID results of pooled human plasma, urine and feces using LC/HRMS. The results indicate that the parent drug is the major pharmacological component exposed, while multiple minor metabolites are present in plasma. Metabolite M3 and M4 (glucuronidation) and M7 (mono-oxygenation metabolite) are most likely the major metabolites in urine and feces, suggesting that the formation of M3/M4 and M7 may be major metabolic clearance pathways in human. Several minor metabolic pathways lead to minor metabolites in urine and feces. The parent drug is a major drug-related component in feces, which may be unabsorbed, excreted into bile and/or from hydrolysis of M3 and M4 and other glucuronides in feces. The parent drug is a minor drug-related component in urine, suggesting that direct excretion of the parent drug from kidney to urine is not a major clearance pathway.
-
Experience
-
16+
Years of experience
-
500+
Submissions of IND applications
-
2000+
Screening projects
Instruments and Software
-
Instruments
-
Software
-
-
Thermo Orbitrap Eclipse™ Tribrid™
-
Thermo Orbitrap Exploris™ 480
-
Thermo Q-Exactive™ HF
-
Waters VION™ IMS QTof
-
Thermo Q-Exactive™ Plus
-
Thermo Q-Exactive™
-
Therno LTQ Orbitrap XL
-
Waters Xevo®G2 QTof
-
Solid scintillation counter: off-line detection of radioactivity
-
Liquid scintillation counter: total radioactivity detection
-
On-line detection of radioactivity
-
-
-
Thermo Scientific™ Compound Discoverer™
-
Thermo Scientific™ Mass Frontier™
-
Thermo Scientific™ Metworks™
-
Waters MetaboLynxTM
-
Mass Analytical Mass-MetaSite
-
Waters UNIFI®
-
Thermo Scientific™ Biopharma Finder™
-
FAQs
-
What is in vivo metabolite identification?
Metabolite profiling and identification studies in plasma, urine, feces, bile, tissues of animal and plasma, excreta of human are conducted to reveal the distribution information of drugs and their metabolites, and to evaluate metabolites in the circulation and their metabolic clearance pathways.
-
What role does in vivo metabolite identification play in safety assessments?
Metabolite detection and identification of a non-radiolabeled drug in animals and human are often conducted in late discovery and early clinical study, respectively. Profiling and identification of metabolites in plasma may provide the information on what metabolites are exposed to animals and human, what are their abundances relative to the parent drug and what are major metabolites in animal or human circulation. Comparison between the metabolite exposure in human and toxicological species can verify whether the safety of major metabolites in human is adequately evaluated in toxicological species. Profiling and identification of metabolites in urine, feces and/or bile may provide the information of metabolic clearance pathways in animals and human, which can be utilized to correlate in vitro and in vivo metabolism.
Related Resources
-
Metabolite Identification in Peptide Drugs and Its Challenges
ArticlesDec 02, 2024Learn More -
Comparative Metabolite Profiling and Identification of a GalNAc-Conjugated siRNA, siRNA01, in Plasma Prepared with Various Anticoagulants, Serum, and In Vivo Plasma Using LC-UV-HRMS
PostersOct 25, 2024Learn More -
Overcoming Challenges in Precise Structural Identification of Target Metabolites
WebinarsOct 12, 2024Learn More -
Involvement of Aldehyde Oxidase (AOXs) in Drug Metabolism: Early Prediction and Coping Strategies
ArticlesSep 26, 2024Learn More -
Comparative Metabolite Profiling and Identification of a GalNAc-Conjugated siRNA, siRNA01, in Plasma Prepared with Various Anticoagulants, Serum, and In Vivo Plasma Using LC-UV-HRMS
PostersSep 14, 2024Learn More -
Prodrug Approaches for Improved DMPK Characteristics and Their Preclinical Study Considerations
ArticlesAug 29, 2024Learn More -
Navigating the Path from IND to NDA
BlogsAug 01, 2024Learn More -
An Analytical Workflow for Polymer Metabolism: PEGylated Lipids Biotransformation with LC-HRMS
PostersJun 27, 2024Learn More -
Development of a Convenient In Vitro Method for Predicting Metabolism and Disposition of Acrylamide Covalent Drugs in Humans
PostersMar 21, 2024Learn More -
What Are Metabolite Profiling & Identification Studies?
BlogsFeb 05, 2024Learn More -
Effect of pH on Metabolite Profiling and Identification of GalNAc Conjugated siRNA in In Vitro Metabolic System
PostersJan 23, 2024Learn More -
Metabolite Profiling and Identification of Oligonucleotide in In Vitro Metabolic System
PostersOct 30, 2023Learn More -
DAR Distribution Determination for Antibody-drug-conjugates (ADCs) by LC-HRMS in In Vitro and In Vivo Studies
PostersOct 27, 2023Learn More -
Drug Metabolism and Pharmacokinetics (DMPK) Service
BrochuresOct 27, 2023Learn More -
One-stop Metabolite Biosynthesis and Structural Characterization
BrochuresOct 27, 2023Learn More -
Overcoming the Challenges of Metabolite Identification and Profiling for Developing Oligonucleotides
BlogsOct 20, 2023Learn More -
Metabolite Profiling & Identification (MetID) Services
BrochuresOct 19, 2023Learn More -
Oligonucleotide Drugs: Strategies for Metabolism and Metabolite Profiling and Identification
ArticlesSep 13, 2023Learn More -
In Vitro-In Vivo Metabolite Profiling and Identification of Oligonucleotide
PostersAug 30, 2023Learn More -
A New Method to Improve Identification of the Payload-Containing Catabolites of ADCs
BlogsAug 10, 2023Learn More -
How to Address the Challenges of PROTAC Metabolism
BlogsJul 13, 2023Learn More -
How MetID Studies can Improve Safety and Efficacy in PROTAC Drugs
ArticlesJul 07, 2023Learn More
Reference
- 1.
C. E. Hop, Z. Wang, Q. Chen, G. Kwei, Plasma-Pooling Methods to Increase Throughput for in vivo Pharmacokinetic Screening, J. Pharm. Sci., 87 (1998) 901-903.
Stay Connected
Keep up with the latest news and insights.